MEDX Breaks Through to New 52-Week High: A Beacon for Value Investors** ### 说明：

Horizon Kinetics Medical ETF (MEDX.O) Hits 52-Week High Amid Active Healthcare Exposure

The Horizon Kinetics Medical ETF (MEDX.O) is an actively managed equity ETF focused on global healthcare companies with an emphasis on cancer research and pharmaceutical innovation. With a 0.85% expense ratio and a 1.0x leverage ratio, the fund takes long positions in its targeted sectors. On November 14, 2025, the ETF experienced a net outflow of $28,718.90 through small orders, while no significant inflows were recorded through block or extra-large orders. This suggests retail or institutional investors may be selectively rotating capital rather than making large-scale commitments.

The ETF’s recent surge to a 52-week high coincided with a technical signal indicating overbought conditions. According to market data, the Relative Strength Index (RSI) for MEDX.O triggered an overbought alert on November 17, 2025, raising caution about potential near-term volatility. While strong demand for healthcare innovation remains a tailwind, the overbought status suggests investors should monitor for profit-taking or consolidation patterns in the coming weeks.

Among peer medical and healthcare ETFs, MEDX.O holds a moderate expense ratio of 0.85% compared to industry benchmarks like the iShares Core U.S. Aggregate Bond ETF (AGG.P), which charges just 0.03%. However, its $33.15 share price and 1.0x leverage position it as a more aggressive option relative to unleveraged alternatives. The fund’s active management approach contrasts with passive counterparts like AGG.P, which manages $134 billion in assets, highlighting its niche focus on biotech and pharmaceutical advancements.

For investors evaluating alternatives, the peer ETF landscape reveals a wide dispersion in assets and costs. The iShares Core U.S. Aggregate Bond ETF (AGG.P) dominates with $134 billion in AUM but offers a mere 0.03% expense ratio. In contrast, the Active Income ETF (ACVT.P) charges 0.65% while managing just $27 million. MEDX